AstraZeneca should stick to its winning formula. It doesn’t need a $400bn US mega-merger

The Anglo-Swedish drugmaker’s flirtation with a grand combo with US group Bristol Myers Squibb is baffling

Opens the original publisher in a new tab. Full articles belong to their publishers; a subscription may be required.